INSMED Inc. Files 8-K Report

TL;DR

INSMED filed a routine 8-K on 6/6/25, no major news.

AI Summary

On June 6, 2025, INSMED Inc. filed an 8-K report detailing "Other Events." The filing does not contain specific financial transactions or material business updates, but rather serves as a notification of events as required by the SEC. The report was filed with the SEC and pertains to INSMED Inc., a pharmaceutical preparations company incorporated in Virginia.

Why It Matters

This filing indicates that INSMED Inc. is adhering to its regulatory reporting obligations with the SEC. Investors should review the full filing for any potential implications, though this specific report does not detail new material information.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report for 'Other Events' and does not disclose any new material risks or significant business changes.

Key Players & Entities

• INSMED Inc. (company) — Registrant
• June 6, 2025 (date) — Date of Report
• Virginia (location) — State of Incorporation
• 700 US Highway 202/206 Bridgewater, New Jersey 08807 (address) — Principal Executive Offices
• 000-30739 (other) — Commission File Number
• 54-1972729 (other) — IRS Employer Identification No.

FAQ

From the Filing

0001140361-25-021810.txt : 20250606 0001140361-25-021810.hdr.sgml : 20250606 20250606170028 ACCESSION NUMBER: 0001140361-25-021810 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250606 ITEM INFORMATION: Other Events FILED AS OF DATE: 20250606 DATE AS OF CHANGE: 20250606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 251031875 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 8-K 1 ef20050184_8k.htm 8-K false 0001104506 NASDAQ 0001104506 2025-06-06 2025-06-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 700 US Highway 202/206 Bridgewater , New Jersey   08807 (Zip Code) (Address of principal executive offices)     Registrant’s telephone number, including area code: ( 908 ) 977-9900 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share INSM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01 - Other Events On June 6, 2025 (the “Redemption Date”), Insmed Incorporated (the “Company”) completed its previously announced redemption of all of the aggregate principal amount outstanding of its 0.75% Convertible Senior Notes due 2028 (the “Notes”). Outstanding Notes in the aggregate principal amount of $1,965,204.69 that had not already been converted by holders thereof were redeemed for cash at a redemption price equal to 100% of the principal amount of such Notes, plus accrued and unpaid interest on such Notes to, but excluding, the Redemption Date. The redemption was effected pursuant to the terms of the Indenture, dated as of January 26, 2018, as supplemented by the Second Supplemental Indenture, dated as of May 13, 2021, between the Company and Computershare Trust Company, N.A., as successor trustee to Wells Fargo Bank, National Asso